A recently published study demonstrated that MPT0E014, a novel HDAC inhibitor, decreased the expression of angiotensin II receptor and TGF-β1 in cardiac fibroblasts, inhibited their proliferation and migration, and reduced cardiac fibrosis in heart failure rats, which highly signified the direct antifibrotic activity through HDAC inhibition [14]. Here, TGFB1 is linked to heart failure.